Bone-Strengthening Discovery Could Reverse Osteoporosis

Researchers at Leipzig University identified the GPR133 receptor as a key regulator of bone strength.

In mouse studies, activating GPR133 with AP503 increased bone formation, reduced bone breakdown, and improved bone density.

The benefits were seen in both healthy mice and osteoporosis models, pointing to a potential new drug target.

The finding could help open new treatments for osteoporosis and possibly therapies for combined age-related bone and muscle loss.